Radioligand Therapy 177Lu-PSMA-617 in Progressive PSMA-positive mCRPC

Andrew J. Armstrong, MD, MSc, evaluates the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.